LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Home・Aandelen Lijst・AnaptysBio Inc

AnaptysBio Inc

Gesloten

SectorGezondheidszorg

58.53 -6.7

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

58.18

Max

63.74

Belangrijke statistieken
By Trading Economics
Inkomsten	35M 50M
Verkoop	32M 108M
Winstmarge	45.833
Werknemers	104
EBITDA	29M 68M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+28.69% upside

Dividenden
By Dow Jones
Volgende Winsten	4 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	441M 2B
Vorige openingsprijs	65.23
Vorige sluitingsprijs	58.53

Nieuwssentiment

By Acuity

39%

61%

117 / 345 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

19.25 / 21.135 Steun & Weerstand

AnaptysBio Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 mei 2026, 23:10 UTC

Populaire aandelen

Stocks to Watch: Agilysys, XP

18 mei 2026, 18:44 UTC

Belangrijke Marktbewegers

Claritev Shares Recover After Comments About DOJ

18 mei 2026, 23:55 UTC

Winsten

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 mei 2026, 23:47 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

18 mei 2026, 23:47 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 mei 2026, 23:37 UTC

Marktinformatie

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 mei 2026, 22:31 UTC

Acquisities, Fusies, Overnames

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 mei 2026, 22:30 UTC

Acquisities, Fusies, Overnames

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 mei 2026, 22:30 UTC

Acquisities, Fusies, Overnames

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 mei 2026, 22:25 UTC

Acquisities, Fusies, Overnames

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 mei 2026, 22:24 UTC

Acquisities, Fusies, Overnames

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

18 mei 2026, 20:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

18 mei 2026, 20:25 UTC

Winsten

Correct: XP 1Q Total Client Assets BRL1.53T

18 mei 2026, 20:23 UTC

Winsten

XP 1Q Total Client Assets BRL1.53B

18 mei 2026, 20:19 UTC

Winsten

XP 1Q Adj EPS BRL2.49 >XP

18 mei 2026, 20:19 UTC

Winsten

XP 1Q Rev BRL4.73B >XP

18 mei 2026, 19:10 UTC

Marktinformatie

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 mei 2026, 19:00 UTC

Winsten

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 mei 2026, 18:52 UTC

Marktinformatie

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 mei 2026, 18:17 UTC

Marktinformatie

Acquisities, Fusies, Overnames

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 mei 2026, 17:22 UTC

Marktinformatie

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 mei 2026, 16:57 UTC

Acquisities, Fusies, Overnames

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 mei 2026, 16:57 UTC

Marktinformatie

Global Energy Roundup: Market Talk

18 mei 2026, 16:57 UTC

Marktinformatie

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 mei 2026, 16:54 UTC

Acquisities, Fusies, Overnames

Vinci Doesn't Set Out Financial Details of Deal

18 mei 2026, 16:50 UTC

Acquisities, Fusies, Overnames

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 mei 2026, 16:49 UTC

Acquisities, Fusies, Overnames

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 mei 2026, 16:49 UTC

Acquisities, Fusies, Overnames

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 mei 2026, 16:48 UTC

Acquisities, Fusies, Overnames

Vinci Buys Canada's Modern Group of Companies

Peer Vergelijking

Prijswijziging

AnaptysBio Inc Prognose

Koersdoel

By TipRanks

28.69% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 81.27 USD 28.69%

Hoogste 140 USD

Laagste 50 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor AnaptysBio Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan AnaptysBio Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

19.25 / 21.135Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

117 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.